<DOC>
	<DOCNO>NCT00739973</DOCNO>
	<brief_summary>Evaluate efficacy ( blood pressure lower effect ) safety aliskiren alone combination amlodipine patient essential hypertension .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Aliskiren Alone Combination With Amlodipine Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>msDBP ≥ 90 mmHg &lt; 110 mmHg visit prior Visit 3 ( Visit 2 optional Visit 201 ) msDBP ≥ 95 mmHg &lt; 110 mmHg Visit 3 ( Day 1 / randomization ) . All patient must absolute difference ≤ 10 mmHg msDBP last 2 visit singleblind runin period ( Visit 2 3 Visits 201 3 ) . Severe hypertension Pregnant nursing ( lactate ) woman Women childbearing potential Previous current diagnosis heart failure ( NYHA Class IIIV ) . Serum potassium ≥ 5.3 mEq/L ( mmol/L ) Visit 1 . Uncontrolled Type 1 Type 2 diabetes mellitus Hypersensitivity renin inhibitor , calcium channel blocker , drug Similar chemical structure History malignancy within 5 year History hypertensive encephalopathy cerebrovascular accident , history transient ischemic attack ( TIA ) , myocardial infarction , coronary bypass surgery , percutaneous coronary intervention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Hypertension , Aliskiren , Amlodipine</keyword>
</DOC>